Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Jerrold B. GrossmanDirector | Adma BiologicsADMA | Open-market buy | 05/27 | 05/28 | 6,400 sh | $7.91 | $50,624 | +1.2% |
Jerrold B. GrossmanDirector | Adma BiologicsADMA | Open-market buy | 05/12 | 05/14 | 12,500 sh | $8.01 | $100,125 | +2.5% |
Jerrold B. GrossmanDirector | Adma BiologicsADMA | Open-market buy | 05/11 | 05/12 | 12,500 sh | $8.01 | $100,125 | +2.6% |
Adma BiologicsADMA | Open-market sale10b5-1 plan | 03/16 | 03/17 | 21,000 sh2 trades | $15.16avg. | $318,360 | −1.0% | |
Kaitlin M. Kestenberg-MessinaCOO and SVP, Compliance | Adma BiologicsADMA | Open-market sale | 03/09 | 03/10 | 10,096 sh | $15.63 | $157,800.48 | −2.1% |
Adma BiologicsADMA | Open-market buy | 03/05–03/06 | 03/09 | 14,000 sh2 trades | $15.53avg. | $217,420 | +0.7% | |
Adma BiologicsADMA | Open-market sale10b5-1 plan | 02/17 | 02/17 | 21,000 sh2 trades | $16.08avg. | $337,680 | −0.9% | |
Adma BiologicsADMA | Open-market sale10b5-1 plan | 25/12/15 | 25/12/16 | 21,000 sh2 trades | $19.79avg. | $415,590 | −1.0% | |
Adma BiologicsADMA | Open-market sale10b5-1 plan | 25/11/19 | 25/11/21 | 21,000 sh2 trades | $16.00avg. | $336,000 | −1.0% | |
Adma BiologicsADMA | Open-market sale10b5-1 plan | 25/10/24 | 25/10/24 | 21,000 sh2 trades | $16.00avg. | $336,000 | −1.0% | |
Adma BiologicsADMA | Open-market sale10b5-1 plan | 25/09/15 | 25/09/16 | 21,000 sh2 trades | $16.13avg. | $338,730 | −1.0% | |
Adma BiologicsADMA | Open-market sale10b5-1 plan | 25/08/15 | 25/08/15 | 21,000 sh2 trades | $16.88avg. | $354,480 | −1.0% | |
Adma BiologicsADMA | Open-market sale10b5-1 plan | 25/07/15 | 25/07/16 | 21,000 sh2 trades | $18.66avg. | $391,860 | −1.0% | |
Adma BiologicsADMA | Open-market sale10b5-1 plan | 25/06/16 | 25/06/18 | 21,000 sh2 trades | $20.81avg. | $437,010 | −1.0% | |
Adma BiologicsADMA | Open-market sale | 25/06/12–25/06/16 | 25/06/16 | 425,621 sh3 trades | $20.74avg. | $8,829,333.47 | No record | |
Lawrence P. GuiheenDirector | Adma BiologicsADMA | Open-market sale | 25/06/09 | 25/06/11 | 20,000 sh | $20.96 | $419,200 | −17.4% |
Jerrold B. GrossmanDirector | Adma BiologicsADMA | Open-market sale | 25/06/09 | 25/06/10 | 10,000 sh | $21.31 | $213,100 | −2.0% |
Adma BiologicsADMA | Open-market sale | 25/05/21–25/05/22 | 25/05/23 | 9,000 sh2 trades | $20.29avg. | $182,635.8 | −7.3% | |
Adma BiologicsADMA | Open-market sale10b5-1 plan | 25/05/15 | 25/05/16 | 21,000 sh2 trades | $19.45avg. | $408,450 | −1.0% | |
Adma BiologicsADMA | Open-market sale10b5-1 plan | 25/04/15 | 25/04/16 | 21,000 sh2 trades | $21.46avg. | $450,660 | −1.0% |